echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Flow mark and abandoned mark appear. Why does someone shout "against unfair competition" at the site of volume purchasing

    Flow mark and abandoned mark appear. Why does someone shout "against unfair competition" at the site of volume purchasing

    • Last Update: 2020-01-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    No 1800, Tianshan Road, Shanghai again set off a "frenzy of bargain" On the night of January 17, the joint procurement office released the results of the national drug centralized procurement The final results showed that of the 33 varieties collected, 32 varieties were successfully negotiated, sodium bicarbonate flow standard According to official data, the average price reduction of this centralized mining reached 53%, with a maximum reduction of 93% In particular, the antidiabetic drugs acarbose, glimepiride and other chronic diseases are often used The average decline of foreign investment in the original research and development of drugs was 82%, and that of generic drugs was 51% On the same day, unexpectedly, the enterprises involved in bid abandonment and variety flow again appeared Hansen pharmaceutical, Fuyao pharmaceutical and Yuanda Pharmaceutical (China) participated in the bidding of sodium bicarbonate, but the competition seems not too cruel, and the drug has become the only flow bidding product in this collection In the negotiation, the flow of bidding means that the high decline in the quotation process still fails to meet the expectations of the purchaser However, this kind of flow bidding is not intentionally done by the enterprise According to the explanation of the field staff, the flow bidding is caused by the wrong price of the enterprise participating in the bidding In fact, it is not the first time that there is a flow of drugs In the bidding procurement of "4 + 7" pilot volume procurement at the end of 2018, some enterprises chose the flow of drugs due to their unwillingness to reduce too much However, it is dramatic that at that time, the flow of drugs enterprises later went to find the head of the National Health Insurance Bureau and asked if they could give another chance, which is regretful It can be said that after several rounds of negotiations, the official has gradually mastered the rules of the game with the pharmaceutical companies, and the bargaining space for enterprises to face the official tough attitude will be less and less, so the price reduction has become a compulsory course for enterprises rather than an elective course Due to the wrong price calculation by the enterprise, the sodium bicarbonate flow label was placed in the second batch of bidding site for volume purchase, which was used to alleviate the flow label of sodium bicarbonate tablets, the medicine for stomach pain and heartburn caused by too much acid It is the only flow label variety this time This means that all offers are invalid, and the result is not the negative bidding of the enterprise, but the wrong price At the quotation site, Yuanda pharmaceutical and Hunan Hansen pharmaceutical participated in the bidding of this variety According to the on-site staff, the quotations of the two enterprises are higher than the ceiling price of 0.11 yuan / piece, and the difference is only 0.009 yuan and 0.013 yuan In fact, the reason why the price is miscalculated is that the price difference comparison rule is adopted in the bidding For different dosage forms and specifications of the same drug, the price shall be determined based on the price of the representative product according to the prescribed drug difference comparison relationship, and the amount finally used for the price comparison shall be multiplied by a certain factor For example, the corresponding coefficients of sustained-release tablets, regular release tablets and capsules under the same variety are different The result to be awarded is to multiply the difference ratio coefficient of corresponding dosage forms on the basis of enterprise quotation, and then determine the final result The bidding enterprises that did not find out this algorithm are the most confused bidders in this bidding In addition, Sanofi, as the original research manufacturer with a large price cut in the "expansion" of volume procurement at the end of 2019, did not participate in the bidding of glimepiride tablets (1mg) on the same day Sanofi, the original research pharmaceutical company, considered that it actively chose to abandon the bidding Chongqing kangkeri Pharmaceutical Co., Ltd offered 0.053 yuan / tablet to win the bid From the current published price, the lowest bid price of glimepiride is 0.053 yuan / tablet in the 2mg specification, while the highest effective bid price set for this centralized purchase is 0.30 yuan / tablet The current price of Sanofi glimepiride (trade name: Amory) is 4.33 yuan / tablet, which means Sanofi needs to be reduced by more than 90% to be eligible, so Sanofi chooses to withdraw As a matter of fact, Sanofi's choice to withdraw is also traceable Because China's pharmaceutical market was not sound for a long time and the quality of generic drugs was uneven, some of the original research drugs that had passed the patent period in the international market did not appear in China even though they had passed the patent period Many of the drugs that had passed the patent period still sold well Now the government vigorously promotes them Centralized purchase of drugs is to change this phenomenon In an interview with reporters, Shi lichen, founder of Beijing Dingchen Management Consulting Co., Ltd., also said that when foreign companies' original research drugs enter the Chinese market, they all have a certain period of patent protection, and the "welfare" enjoyed by these original research drugs in the Chinese market has far exceeded the scope of patent protection period Therefore, consumers are more recognized by the original research enterprise Therefore, the original research enterprise will think that even if some varieties flow standard, consumers will still spend a high price to buy, there is no need to reduce the price Through the sharp price reduction of drugs, the limited medical insurance funds are saved, so the chance of generic drugs will come, so some original pharmaceutical companies like Sanofi began to give up the market Of course, if we don't want this market, Bayer, a multinational pharmaceutical company, has set an example for the latecomers In the quotation process of the same day, Bayer, the original research drug factory, offered a price of 50 mg 5.42 yuan / box (30 tablets) for acarbose, a kind of hypoglycemic drug This is nearly 80% lower than the maximum effective declaration price of 0.8353 yuan / tablet, and the overall decline is more than 90% According to the public information, the median price of Acarbose Tablets of Bayer was 2.14 yuan / tablet for 50mg and 3.53 yuan / tablet for 100mg Another enterprise winning the bid of this variety is LVYE pharmaceutical, with the bid price of 9.6 yuan / box The prices of Beijing Fuyuan and China, the United States and East China are about 0.47 yuan / tablet and 0.43 yuan / tablet, respectively, because they are 1.8 times higher than the lowest price The products of these two enterprises are directly out of business It can be said that Bayer, as the original research drug manufacturer, has quoted a price far lower than that of the generic drug manufacturer, which is beyond the imagination of other competitors According to the surging news article "the second batch of drugs with volume purchase four times: Bayer reported the lowest price in the world, and was questioned about dumping", a representative of an enterprise out of the Bureau called out "unfair competition, anti-dumping!" This is a resounding slogan In fact, the reason why multinational pharmaceutical companies choose not to reduce prices is that, for multinational pharmaceutical companies, their quotation mainly depends on two aspects: first, the importance and development strategy of Chinese market; second, the proportion of sales volume of Chinese market in its global market Some large varieties of drugs, the original research enterprises did not give low prices, because the Chinese market is not its mainstream market at present If its price in China continues to fall, it will lower its global lowest price At the same time, some enterprises will also consider from the perspective of future development If the company's product line is sufficient and many new drugs will be launched in China in the next few years, the enterprises will pay more attention to the development of new drugs, so they are unwilling to participate in the price war of generic drugs market in the way of price for quantity However, there must be special cases China's pharmaceutical market is different from any other region in the world Once winning the bid in volume procurement, it will have a very broad market space Now, for enterprises like Sanofi who choose to abandon the bid, it is still a question mark whether they will reduce their prices to occupy the remaining space in the future, In fact, multinational pharmaceutical companies did not participate in volume procurement, and there was precedent for later price reduction In the last round of centralized procurement, Lipitor, a lipid-lowering drug of Pfizer, did not participate in volume procurement bidding At that time, Beijing Jialin pharmaceutical, a subsidiary of dexhan health, successfully bid Later, Pfizer's similar original research drugs could not resist the pressure, but chose to reduce the price On March 26 last year, Sichuan Provincial Pharmaceutical Machinery bidding and purchasing service center issued a notice that Pfizer's Lipitor 10mg, 7-piece package specifications were reduced by 42.03% locally In fact, at present, our country is redoubling its efforts to reform the medical system, preparing to reduce the price of non patent drugs and save state funds to help develop new and cutting-edge drugs The move puts pressure on the profitability of many pharmaceutical companies China used to be a lucrative market for generic drugs for global pharmaceutical companies, and now these companies must adapt to the new normal, the Singapore associated Morning Post said in a commentary 37 statement: This article only represents the author and does not represent the position of yaozhi.com You are welcome to communicate and supplement in the message area If you need to reprint, please be sure to indicate the author and source of the article.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.